1. Home
  2. KMPR vs NTLA Comparison

KMPR vs NTLA Comparison

Compare KMPR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KMPR

Kemper Corporation

HOLD

Current Price

$28.51

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$11.94

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMPR
NTLA
Founded
1990
2014
Country
United States
United States
Employees
7400
N/A
Industry
Property-Casualty Insurers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
KMPR
NTLA
Price
$28.51
$11.94
Analyst Decision
Hold
Buy
Analyst Count
5
23
Target Price
$47.67
$20.02
AVG Volume (30 Days)
813.2K
4.2M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
3.85%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.35
$62.75
P/E Ratio
$14.38
N/A
Revenue Growth
N/A
16.92
52 Week Low
$22.69
$7.95
52 Week High
$54.90
$28.24

Technical Indicators

Market Signals
Indicator
KMPR
NTLA
Relative Strength Index (RSI) 56.87 40.65
Support Level $29.76 $10.94
Resistance Level $30.97 $15.52
Average True Range (ATR) 1.16 0.58
MACD 0.01 0.07
Stochastic Oscillator 67.92 76.16

Price Performance

Historical Comparison
KMPR
NTLA

About KMPR Kemper Corporation

Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: